PetVivo Holdings, Inc. Adds Daniel P. Collins as Chief Science Officer
August 28, 2018 at 12:00 pm
Share
PetVivo Holdings, Inc. announced the addition of Daniel P. Collins, Ph.D., as Chief Science Officer (CSO). Dr. Daniel Collins has over 30 years of medical industry experience. He co-founded CytoMedical Design, LLC in 2012 serving as its Chief Science Officer. Previously, he co-founded BioE, Inc., in 1993 and served as its Executive Vice President, Chief Scientific Officer and Board member. Before founding BioE, Dr. Collins was Director of R&D Systems, Inc.’s Flow Cytometry Products department; Director of Coulter Corporation’s hematology lab within its Immunology division; and Director of the Harrington Cancer Center’s Immunology, Hematology and Oncology specialty laboratory.
PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Companyâs lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a bodyâs cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.
PETVIVO HOLDINGS, INC. 
